Kirin Holdings

LC-Plasma-based Vaccine Research Selected for SCARDA Project

Retrieved on: 
Mercoledì, Maggio 8, 2024
Health, Infectious Diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Infection, Kirin Holdings, Christian democracy, Postbiotic, Holding company, SARS-CoV-2, Bacteria, Plasma, Vaccine, Urinary tract infection, Immunization, Research and development, Virus, Kirin, Medical research, Multimedia, AMED, BBRC

We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).

Key Points: 
  • We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).
  • View the full release here: https://www.businesswire.com/news/home/20240507111790/en/
    This research aims at developing an intranasal LC-Plasma vaccine to induce innate immunity for prevention of respiratory virus infection.
  • SCARDA was established at AMED in March, 2022, based on the national strategy, to strengthen strategic research funding and to promote the formation of world-class research and development centers ( https://www.amed.go.jp/en/program/list/21/index.html ).
  • This project is to explore the potential of intranasal LC-Plasma vaccination to prevent respiratory infection with viruses including SARS-CoV-2 and influenza viruses.

MHI and Mitsubishi Logisnext Receive First Order from Kirin Group for an Automated Picking Solution

Retrieved on: 
Venerdì, Dicembre 8, 2023
Kirin Holdings, Mitsubishi Logisnext, YHH, MHI, Intelligence, Automation, Warehouse

The system will be implemented at the Ebina Logistics Center in Ebina, Kanagawa Prefecture, managed by Kirin Group Logistics (East Japan Regional Office, Shonan Branch Office).

Key Points: 
  • The system will be implemented at the Ebina Logistics Center in Ebina, Kanagawa Prefecture, managed by Kirin Group Logistics (East Japan Regional Office, Shonan Branch Office).
  • The automated picking system is the first automated system in Japan to utilize automated guided forklifts (AGFs), automated guided vehicles (AGVs), and palletizers(3) for the picking process.
  • In November 2022, MHI Group and Kirin Group began a joint demonstration project with the aim of introducing MHI Group's automated picking solutions for beverage warehouses, which require heavy load handling operations by logistics operators(4).
  • (4) For more information on the start of the joint demonstration of an automated picking solution with Kirin Group, please refer to the following press release.

Kyowa Hakko Bio Celebrates Grand Opening of Expanded Cognizin® Citicoline Manufacturing Facility in Hofu, Japan

Retrieved on: 
Venerdì, Dicembre 22, 2023
Kyowa Kirin, Attention, Kirin Holdings, Health, Ageing, Growth, Rare-earth element

NEW YORK, Dec. 22, 2023 /PRNewswire-PRWeb/ -- Kyowa Hakko Bio Co., Ltd. (Kyowa Hakko Bio) & Kyowa Hakko USA, Inc (Kyowa), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), is thrilled to announce the celebration of the grand opening of its expanded citicoline manufacturing facilities at the Kyowa Hakko Bio Yamaguchi Production Center, situated in Hofu City, Yamaguchi Prefecture, Japan. The momentous occasion, marks a significant milestone in the company's growth journey. Kyowa Hakko Bio President and CEO, Ms. Yuki Kanzaki, underscored the pivotal role of Cognizin in the company's future success.

Key Points: 
  • Kyowa Hakko Bio Co., Ltd. (Kyowa Hakko Bio) & Kyowa Hakko USA, Inc (Kyowa), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), is thrilled to announce the celebration of the grand opening of its expanded citicoline manufacturing facilities at the Kyowa Hakko Bio Yamaguchi Production Center, situated in Hofu City, Yamaguchi Prefecture, Japan.
  • NEW YORK, Dec. 22, 2023 /PRNewswire-PRWeb/ -- Kyowa Hakko Bio Co., Ltd. (Kyowa Hakko Bio) & Kyowa Hakko USA, Inc (Kyowa), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), is thrilled to announce the celebration of the grand opening of its expanded citicoline manufacturing facilities at the Kyowa Hakko Bio Yamaguchi Production Center, situated in Hofu City, Yamaguchi Prefecture, Japan.
  • Kyowa Hakko Bio President and CEO, Ms. Yuki Kanzaki, underscored the pivotal role of Cognizin in the company's future success.
  • She emphasized that through the stable supply of citicoline, Kyowa Hakko Bio continues to contribute to improving cognitive health, focus, and attention, addressing essential aspects of overall well-being.

Kirin Group chooses Board, the leader in Intelligent Planning, to complete its financial transformation

Retrieved on: 
Giovedì, Dicembre 14, 2023
Technology, Finance, Consulting, Fintech, Other Technology, Professional Services, Software, Data Management, Other Professional Services, Kirin Holdings, Drink, FP&A, Strategic planning, Kirin, Intelligence, Finance department, Punjab (Pakistan), Go go, Ministry of Finance, Economic Development Board, Management, Food, Medication

Kirin Group is known for globally recognized products including Kirin ICHIBAN and Gogo-no-Kocha.

Key Points: 
  • Kirin Group is known for globally recognized products including Kirin ICHIBAN and Gogo-no-Kocha.
  • In 2021, Kirin Holding built a new team to lead corporate FP&A efforts and effectively drive the group's long-term strategic planning.
  • Board appears to be the right solution to complete Kirin’s financial transformation.
  • Our FP&A efforts will contribute to our company’s further growth"
    “We are delighted to support Kirin’s Financial transformation with our proven Intelligent Planning Solutions.

Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!

Retrieved on: 
Lunedì, Novembre 27, 2023
Retail, Health, Fitness & Nutrition, General Health, Vitamins, Supplements, Food, Beverage, Biotechnology, Sale, Capsule, PubMed, Lactococcus lactis, Immunity, Research, Immune system, Kao Corporation, Plasma, Coffee, Government, Polyphenol, Multimedia, Christian democracy, Consumer Affairs Agency, Kirin, Invention, University, BMI, Imperial, Kirin Holdings, IMUSE, Human, Lipid metabolism, Growth, Holding company, Chlorogenic acid, Vaccine, Dietary supplement, Medical device

Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).

Key Points: 
  • Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).
  • This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
  • We are developing a broad lineup of functional food products with immune function claims to help customers solve their health issues.
  • “Kirin iMUSE Immunity Care and Healthya Visceral Fat Down,” which is about to go on sale, is a product born from the joint research project.

Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao

Retrieved on: 
Venerdì, Novembre 24, 2023
COVID-19, Research, Infectious Diseases, Fitness & Nutrition, Other Health, General Health, University, Health, Science, Education, World Health Organization, Odds ratio, Atherosclerosis, Obesity, Immunity, Coronavirus, Conditional sentence, Ageing, Incidence, Atrophy, WHO, Risk, Journal, Facial muscles, Kirin, Kirin Holdings, Wakayama Medical University, Blood, Vaccine, Pharmaceutical industry, Dietary supplement, PDC, PubMed

Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.

Key Points: 
  • Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.
  • For the first time in the world, this collaboration found that people with high visceral fat area levels had low pDC activity.
  • It was also suggested that visceral fat area and pDC activity, respectively, affect susceptibility to novel coronavirus infection and influenza, and that people with high visceral fat area and low pDC activity are particularly susceptible to these diseases.
  • Thus, it can be said that it is important for people with high visceral fat area values and low pDC activity to address both visceral fat mass and immune function.

Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19

Retrieved on: 
Giovedì, Maggio 11, 2023
Science, Research, Pharmaceutical, Health, COVID-19, University, Education, Clinical Trials, Vaccine, First Department, Smell, Kirin Holdings, Food, Anosmia, Rotavirus, Shortness, Headache, SARS-CoV-2, PDC, Consumer Affairs Agency, Clinical trial, Infection, Division, Multimedia, Chest pain, Fatigue, Lactococcus lactis, Pandemic, Patient, Patent, Risk, Fever Dream, Immune system, Internal medicine, Randomized controlled trial, Blood, Viral load, Shortness of breath, Nagasaki University, Cough, Respiratory Medicine, Institute for Plasma Research, Safety, Pharmaceutical industry, Copper, Omicron, Kirin, Anorexia nervosa, Dysgeusia, Limited, Immunity, Lactococcus, Plasma

Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.

Key Points: 
  • Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.
  • lactis strain Plasma*1 (L.lactis Plasma, a postbiotic), researched and developed by Kirin Holdings Company, Limited (Kirin Holdings).
  • Nagasaki University and Kirin Holdings have jointly filed a patent application for the findings of this specified clinical trial.
  • Nagasaki University and Kirin hope that L. lactis Plasma will become one of the new treatment or adjunctive care to patients with mild COVID-19.

Norges Bank Terminates Its Observation On Kirin Holdings

Retrieved on: 
Giovedì, Marzo 23, 2023
Pharmaceutical, Finance, General Health, Health, Banking, Professional Services, Food, Beverage, Retail, Government Pension Fund of Norway, Holding company, Observation, Kirin Holdings, Norges Bank, Council, Kirin, Cryptocurrency, Limited, Ethics

Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) today announces that Norges Bank has terminated its observation on Kirin Holdings on March 22 2023, recognizing the completion of the Myanmar business transfer.

Key Points: 
  • Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) today announces that Norges Bank has terminated its observation on Kirin Holdings on March 22 2023, recognizing the completion of the Myanmar business transfer.
  • Based on a recommendation of Norway’s Council on Ethics*1, Norges Bank placed Kirin Holdings under observation with the possibility of exclusion from its Government Pension Fund Global in March 2021*2.
  • Again, based on the recommendation of the Council on Ethics*4, Norges Bank terminated its observation on Kirin Holdings on March 22 2023*5.
  • See Council on Ethics release dated June 23, 2020, “Recommendation to place Kirin Holdings Co Ltd under observation”

Piano Broadens Global Footprint and Social Media Publishing Capabilities

Retrieved on: 
Martedì, Dicembre 13, 2022
Social media, The X Factor Digital Experience, Jaguar Land Rover, AT, EVP, The Wall Street Journal, Kirin Holdings, IBM, SocialFlow, Internet, CBS, BBC, Attention, Air France, Pianos (club), Acquisition, Nielsen, Organization, Creative industries, Online shopping, Piano, Social

AMSTERDAM, Dec. 13, 2022 /PRNewswire/ -- Piano, a leading digital experience platform, today announced it is increasing its European support team for SocialFlow by Piano to better serve clients worldwide, while also adding enhanced functionality to the platform. Piano acquired SocialFlow, a social distribution and marketing platform for media companies, earlier this year.

Key Points: 
  • Piano acquired SocialFlow , a social distribution and marketing platform for media companies, earlier this year.
  • "We are really excited to bring SocialFlow by Piano to our global markets and to continue adding features to the product," said Michael Silberman, EVP, Strategy and Social, Piano.
  • Piano's acquisition of SocialFlow promised to allow social media teams to optimize engagement and attention across multiple accounts and gain a deeper level of insight into how content is driving revenue.
  • Piano continues to grow rapidly and has expanded its global presence and platform capabilities with the acquisitions of AT Internet and CeleraOne in 2021, and SocialFlow in 2022.

Piano Broadens Global Footprint and Social Media Publishing Capabilities

Retrieved on: 
Martedì, Dicembre 13, 2022
Social media, The X Factor Digital Experience, Jaguar Land Rover, AT, EVP, The Wall Street Journal, Kirin Holdings, IBM, SocialFlow, Internet, CBS, BBC, Attention, Air France, Pianos (club), Acquisition, Nielsen, Organization, Creative industries, Online shopping, Piano, Social

AMSTERDAM, Dec. 13, 2022 /PRNewswire/ -- Piano, a leading digital experience platform, today announced it is increasing its European support team for SocialFlow by Piano to better serve clients worldwide, while also adding enhanced functionality to the platform. Piano acquired SocialFlow, a social distribution and marketing platform for media companies, earlier this year.

Key Points: 
  • Piano acquired SocialFlow , a social distribution and marketing platform for media companies, earlier this year.
  • "We are really excited to bring SocialFlow by Piano to our global markets and to continue adding features to the product," said Michael Silberman, EVP, Strategy and Social, Piano.
  • Piano's acquisition of SocialFlow promised to allow social media teams to optimize engagement and attention across multiple accounts and gain a deeper level of insight into how content is driving revenue.
  • Piano continues to grow rapidly and has expanded its global presence and platform capabilities with the acquisitions of AT Internet and CeleraOne in 2021, and SocialFlow in 2022.